Clinical Trial Update: Autologous BMMNCs Combined With Educational Intervention for ASD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating autologous bone marrow mononuclear cells combined with an educational intervention for autism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• Autologous Bone Marrow Mononuclear Cells (BMMNCs) (bone marrow mononuclear cells)

Snippet

Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology | Conditions: Autism Spectrum Disorder | Phase 2 | Status: COMPLETED